Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder

References

• Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Nasrallah HA, Goldberg JF, Correll CU, et al. Differential diagnosis and therapeutic management of schizoaffective disorder. Ann Clin Psychiatry. 2010 Nov; 22(suppl 1):S1–S2.
   PubMedGoogle Scholar
• McElroy SL, Keck PE Jr, Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry. 1999;60:16.
   PubMed Web of Science ®Google Scholar
• Grunder G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8(3):197–202.
   PubMed Web of Science ®Google Scholar
• Preskorn S. The evolution of antipsychotic drug therapy: resperpine, chlorpromazine and haloperidol. J Psychiatr Pract. 2007 Jul;13(4):253–257.
   PubMedGoogle Scholar
• Macaluso M, McKnight S. Overcoming medication nonadherence in schizophrenia: strategies that can reduce harm. Current Psychiatry. 2013 Nov;12(11):15–20.
   Google Scholar
• Olfson M, Marcus C, Wan G. Treatment patterns for schizoaffective disorder and schiziophrenia among medicaid patients. Psychiatric Services. 2009 Feb;60(2):210–216.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207946
   Google Scholar
• Available from: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022264
   Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022043_invega_toc.cfm
   Google Scholar
• Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010 May;71(5):587–598.  Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020272s078,020588s066,021444s052lbl.pdf
   Google Scholar
• Canuso C, Lindenmayer J, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71(5):587–598.
   PubMed Web of Science ®Google Scholar
• Canuso C, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol. 2012;30(5):487–495.
   Web of Science ®Google Scholar
• Conley R, Gupta S, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22(10):1879–1892.
   PubMed Web of Science ®Google Scholar
• Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47(10):606–616.
   PubMed Web of Science ®Google Scholar
• Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R&D. 2015;15:163–174.
   PubMed Web of Science ®Google Scholar
• Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry. 2005 Oct 1;162(10):1984–1985.
   PubMed Web of Science ®Google Scholar
• Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol. 2013 Oct 1;170(3):532–545.
   PubMed Web of Science ®Google Scholar
• Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol. 2013;170(3):532–545.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Macaluso M. Antipsychotics illness: limited evidence suggests possible efficacy based on known receptor binding affinities. Curr Psychiatr. 2013;12:23–29.
   Google Scholar
• Vermir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36:769–779.
   PubMed Web of Science ®Google Scholar
• Levine M, Lovecchio F, Tafoya P, et al. Paliperidone overdose with delayed onset of toxicity. Ann Emerg Med. 2011;58(1):80–82.
   PubMed Web of Science ®Google Scholar
• Tsay M, Klein-Schwartz W, Anderson B. Toxicity and clinical outcomes of paliperidone exposures reported to U.S. Poison Centers. Clin Toxicol. 2014;52:207–213.
   PubMed Web of Science ®Google Scholar
• Li Q, Wineinger NE, Fu D-J, et al. Genome-wide association study of paliperidone efficacy. Pharmacogenet Genomics. 2017;27(1):7–18.
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Psychopharmacol. 2009;49:1318–1330.
   Google Scholar
• Fu D, Turkoz I, Simonson BS, et al. Paliperidone palmitate once-monthly reduced risk of relapse of psychotic, depressive and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253–262.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez A, Guzman Quilo C. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. Clin Drug Investig. 2013;33:867–876.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Fukui N, Watanabe J, et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol Clin Exp. 2012;27:39–42.
   PubMed Web of Science ®Google Scholar
• Hough D, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25–34.
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L, et al. Single‐and multiple‐dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol. 2009;49(11):1318–1330.
   PubMed Web of Science ®Google Scholar
• Melkersson K. Prolactin elevation of the antipsychotic risperdone is predominatly related to its 9-hydroxy metabolite. Hum Psychopharmacol Clin Exp. 2006;21:529–532.
   PubMed Web of Science ®Google Scholar
• Kerbusch-Herben V, CLeton A, Berwaerts J, et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. Clin Pharmacol Drug Dev. 2014;3(5):371–377.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Kazutoshi K, Ishioka M, et al. Interactions between paliperidone and carbamazepine. Ther Drug Monit. 2013;35(5):649–652.
   PubMed Web of Science ®Google Scholar
• Remmerie B, Ariyawansa J, De Meulder M, et al. Drug-drug interaction studies of paliperidone and divalproex sodium extended-release tablets in healthy participants and patients with psychiatric disorders. J Clin Pharmacol. 2015;56(6):683–692.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry. 2009;42:158–163.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Oct 22]. Available from: http://www.janssen.com/
   Google Scholar